178 related articles for article (PubMed ID: 38396674)
21. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.
Zhang N; Gu J; Yin L; Wu J; Du MY; Ding K; Huang T; He X
Oncotarget; 2016 Dec; 7(49):81389-81401. PubMed ID: 27835609
[TBL] [Abstract][Full Text] [Related]
22. Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients.
Ge J; Zhang X; Zhang B; Zhu L; Zhao M; Gao W; Chen D
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101573. PubMed ID: 33281070
[TBL] [Abstract][Full Text] [Related]
23. Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma.
Welberry C; Macdonald I; McElveen J; Parsy-Kowalska C; Allen J; Healey G; Irving W; Murray A; Chapman C
PLoS One; 2020; 15(5):e0232247. PubMed ID: 32374744
[TBL] [Abstract][Full Text] [Related]
24. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients.
Lin KY; Chen QJ; Tang SC; Lin ZW; Zhang JX; Zheng SM; Li YT; Wang XM; Lu Q; Fu J; Guo LB; Zheng LF; You PH; Wu MM; Lin KC; Zhou WP; Yang T; Zeng YY
BMC Cancer; 2023 Dec; 23(1):1190. PubMed ID: 38053048
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
27. Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma.
Chen LJ; Chang YJ; Chang YJ
Oncologist; 2021 Mar; 26(3):e445-e453. PubMed ID: 32969134
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.
Soresi M; Magliarisi C; Campagna P; Leto G; Bonfissuto G; Riili A; Carroccio A; Sesti R; Tripi S; Montalto G
Anticancer Res; 2003; 23(2C):1747-53. PubMed ID: 12820452
[TBL] [Abstract][Full Text] [Related]
29. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Significance of Preoperative Serum Alpha- fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.
An SL; Xiao T; Wang LM; Rong WQ; Wu F; Feng L; Liu FQ; Tian F; Wu JX
Asian Pac J Cancer Prev; 2015; 16(10):4421-7. PubMed ID: 26028108
[TBL] [Abstract][Full Text] [Related]
31. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems.
Giannini E; Risso D; Botta F; Romagnoli P; Malfatti F; Fumagalli A; Testa E; Podestà E; Chiarbonello B; Polegato S; Testa R
J Intern Med; 2004 Mar; 255(3):399-408. PubMed ID: 14871465
[TBL] [Abstract][Full Text] [Related]
32. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.
Giannini EG; Marenco S; Borgonovo G; Savarino V; Farinati F; Del Poggio P; Rapaccini GL; Anna Di Nolfo M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
Hepatology; 2012 Oct; 56(4):1371-9. PubMed ID: 22535689
[TBL] [Abstract][Full Text] [Related]
33. Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma.
Suh SW; Choi YS
Yonsei Med J; 2017 Jul; 58(4):737-742. PubMed ID: 28540985
[TBL] [Abstract][Full Text] [Related]
34. Expression of β-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein.
Ren YJ; Huang T; Yu HL; Zhang L; He QJ; Xiong ZF; Peng H
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):846-851. PubMed ID: 27924522
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma.
Yamashiki N; Seki T; Wakabayashi M; Nakagawa T; Imamura M; Tamai T; Nishimura A; Inoue K; Okamura A; Arita S; Harada K
Oncol Rep; 1999; 6(6):1229-32. PubMed ID: 10523686
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status.
Shan YF; Huang YL; Xie YK; Tan YH; Chen BC; Zhou MT; Shi HQ; Yu ZP; Song QT; Zhang QY
Med Oncol; 2011 Dec; 28(4):1012-6. PubMed ID: 20571936
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors.
Franck M; Schütte K; Malfertheiner P; Link A
World J Gastroenterol; 2020 Jan; 26(1):86-96. PubMed ID: 31933516
[TBL] [Abstract][Full Text] [Related]
38. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.
Guo Y; Zhao J; Bi J; Wu Q; Wang X; Lai Q
J Hematol Oncol; 2012 Jul; 5():37. PubMed ID: 22760167
[TBL] [Abstract][Full Text] [Related]
40. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
